Page 4 - Jason Lettmann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ALX Oncology (NASDAQ:ALXO – Get Rating) had its price objective lowered by stock analysts at Stifel Nicolaus from $60.00 to $36.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 90.88% from the stock’s previous close. […]

Stifel nicolauStifel nicolausJason lettmannPiper sandlerSecurities exchange commissionCredit suisse groupInvestment advisersOncology company profile get ratingLsv associates llcJefferies financial groupVictory capital management incOncology holdings incGet ratingLifesci capitalSuisse groupDirector jason lettmann